Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Long-Term Immunogenicity Follow-up Trial of Adult and Elderly Subjects Who Have Previously Received an Intramuscular Injection of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine

NCT03039790 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT03039790
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03039790 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Long-Term Immunogenicity Follow-up Trial of Adult and Elderly Subjects Who Have Previously Received an Intramuscular Injection of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Lead sponsor
Takeda
Phase
Phase 2
Overall status
Completed
Start date
February 21, 2017
Completion date
July 22, 2021
Enrollment
528 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers, norovirus